Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 616

1.

Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer.

Hanlon AL, Diratzouian H, Hanks GE.

Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):297-303.

PMID:
12023133
2.
3.
4.

Relationship between prostate volume, prostate-specific antigen nadir, and biochemical control.

Kaminski JM, Hanlon AL, Horwitz EM, Pinover WH, Mitra RK, Hanks GE.

Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):888-92.

PMID:
11958880
5.
6.

PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.

Ray ME, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Shipley WU, Zelefsky MJ, Zietman AL, Kuban DA.

Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1140-50. Epub 2005 Sep 29.

PMID:
16198506
7.

Dose response in prostate cancer with 8-12 years' follow-up.

Hanks GE, Hanlon AL, Epstein B, Horwitz EM.

Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):427-35.

PMID:
12243818
8.

Practical application of biochemical failure definitions: what to do and when to do it.

Kestin LL, Vicini FA, Martinez AA.

Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):304-15.

PMID:
12023134
9.

What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?

Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg DF, Pollack A.

Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1003-10.

PMID:
15752879
10.

Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.

Fitch DL, McGrath S, Martinez AA, Vicini FA, Kestin LL.

Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1430-9. Epub 2006 Jun 12.

PMID:
16765527
11.

Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.

Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.

Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):795-9. Epub 2005 May 31.

PMID:
15925452
12.

Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.

Kollmeier MA, Stock RG, Stone N.

Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):645-53.

PMID:
14529768
13.

Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.

Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A.

Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):415-9.

PMID:
15667961
14.

Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era.

Kupelian PA, Buchsbaum JC, Patel C, Elshaikh M, Reddy CA, Zippe C, Klein EA.

Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):704-11.

PMID:
11849793
15.

Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality.

Zelefsky MJ, Shi W, Yamada Y, Kollmeier MA, Cox B, Park J, Seshan VE.

Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1350-6. doi: 10.1016/j.ijrobp.2008.12.067. Epub 2009 Jun 8.

PMID:
19515504
16.
17.

Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy.

Kestin LL, Vicini FA, Ziaja EL, Stromberg JS, Frazier RC, Martinez AA.

Cancer. 1999 Oct 15;86(8):1557-66.

PMID:
10526285
18.

PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time.

Ciezki JP, Reddy CA, Garcia J, Angermeier K, Ulchaker J, Mahadevan A, Chehade N, Altman A, Klein EA.

Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):512-7. Epub 2005 Oct 6.

PMID:
16213667
19.

Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level < or = 10 ng/ml: radiation therapy or surgery?

Keyser D, Kupelian PA, Zippe CD, Levin HS, Klein EA.

Int J Radiat Oncol Biol Phys. 1997 Jul 1;38(4):723-9.

PMID:
9240638
20.

Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions.

Hanks GE, Hanlon AL, Schultheiss TE, Pinover WH, Movsas B, Epstein BE, Hunt MA.

Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):501-10.

PMID:
9635695

Supplemental Content

Support Center